Recursion Pharmaceuticals's total assets for Q4 2025 were $1.47B, an increase of 5.33% from the previous quarter. RXRX total liabilities were $343.26M for the fiscal quarter, a -2.64% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.